Clinical Trials Browser

Phase 1/2 × Recruiting × trametinib × Clear all

Bile Duct Neoplasms, Cholangiocarcinoma

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

58 enrolled

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT05658640 2025-09-16

HEM-iSMART D

Phase 1/2 Recruiting

26 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

260 enrolled

Plasma cell

Multiple Myeloma

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Phase 1/2 Recruiting

27 enrolled

CNS

Glioma

Clinical Trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

HEM-iSMART D

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas